CDK8/19 inhibition suppresses adaptive resistance to CDK4/6 inhibitors in vitro and in vivo
RNA-seq (gene expression) · human · 44 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 44 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE303026_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1293376 and SRA study SRP601823. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 44 samples.
How we read this: 10 replicated groups read from 44 sample titles; they account for 44 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9116043 500nM Palbo-1 500nM Palbo
- GSM9116044 500nM Palbo-2 500nM Palbo
- GSM9116045 500nM Palbo-3 500nM Palbo
- GSM9116046 500nM Palbo-4 500nM Palbo
- GSM9116047 500nM Palbo-5 500nM Palbo
- GSM9116048 500nM Palbo-6 500nM Palbo
- GSM9116049 500nM Palbo-7 500nM Palbo
- GSM9116050 500nM Palbo-8 500nM Palbo
- GSM9116051 500nM Palbo-9 500nM Palbo
- GSM9116052 500nM Palbo-10 500nM Palbo
- GSM9116053 DMSO Vehicle-1 DMSO Vehicle
- GSM9116054 DMSO Vehicle-2 DMSO Vehicle
- GSM9116055 DMSO Vehicle-3 DMSO Vehicle
- GSM9116056 DMSO Vehicle-4 DMSO Vehicle
- GSM9116057 DMSO Vehicle-5 DMSO Vehicle
- GSM9116058 MCF7 Vehicle DMSO 0.1%-1 MCF7 Vehicle DMSO 0.1%
- GSM9116059 MCF7 Vehicle DMSO 0.1%-2 MCF7 Vehicle DMSO 0.1%
- GSM9116060 MCF7 Vehicle DMSO 0.1%-3 MCF7 Vehicle DMSO 0.1%
- GSM9116061 MCF7 500nM SNX631-1 MCF7 500nM SNX631
- GSM9116062 MCF7 500nM SNX631-2 MCF7 500nM SNX631
- GSM9116063 MCF7 500nM SNX631-3 MCF7 500nM SNX631
- GSM9116064 MCF7 500nM Palbociclib-1 MCF7 500nM Palbociclib
- GSM9116065 MCF7 500nM Palbociclib-2 MCF7 500nM Palbociclib
- GSM9116066 MCF7 500nM Palbociclib-3 MCF7 500nM Palbociclib
- GSM9116067 MCF7 500nM Senexin 631 and 500nM Palbociclib-1 MCF7 500nM Senexin 631 …
- GSM9116068 MCF7 500nM Senexin 631 and 500nM Palbociclib-2 MCF7 500nM Senexin 631 …
- GSM9116069 MCF7 500nM Senexin 631 and 500nM Palbociclib-3 MCF7 500nM Senexin 631 …
- GSM9116070 MCF7 Vehicle Control-1 MCF7 Vehicle Control
- GSM9116071 MCF7 Vehicle Control-2 MCF7 Vehicle Control
- GSM9116072 MCF7 Vehicle Control-3 MCF7 Vehicle Control
- GSM9116073 MCF7 Vehicle Control-4 MCF7 Vehicle Control
- GSM9116074 MCF7 50 mg/kg Palbo-1 MCF7 50 mg/kg Palbo
- GSM9116075 MCF7 50 mg/kg Palbo-2 MCF7 50 mg/kg Palbo
- GSM9116076 MCF7 50 mg/kg Palbo-3 MCF7 50 mg/kg Palbo
- GSM9116077 MCF7 50 mg/kg Palbo-4 MCF7 50 mg/kg Palbo
- GSM9116078 MCF7 50 mg/kg Palbo and 30 mg/kg SNX631-6-1 MCF7 50 mg/kg Palbo and…
- GSM9116079 MCF7 50 mg/kg Palbo and 30 mg/kg SNX631-6-2 MCF7 50 mg/kg Palbo and…
- GSM9116080 MCF7 50 mg/kg Palbo and 30 mg/kg SNX631-6-3 MCF7 50 mg/kg Palbo and…
- GSM9116081 MCF7 50 mg/kg Palbo and 30 mg/kg SNX631-6-4 MCF7 50 mg/kg Palbo and…
- GSM9116082 MCF7 50 mg/kg Palbo and 30 mg/kg SNX631-6-5 MCF7 50 mg/kg Palbo and…
+ 4 more — browse all 44 samples with per-sample file links →
- GSE303100 Dissecting Resistance to CDK4/6 Inhibition in Experimental Glioma via Genome-wide CRISPR-Cas9 Screening 24 samples shares cdk4, inhibition, resistance
- GSE325486 ESR1 mutations shape the clonal dynamics, genetic diversity and cellular states of acquired resistance to CDK4/6 inhibitors 57 samples shares cdk4, resistance, inhibitors
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares inhibition, inhibitors, vitro
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares inhibition, resistance, inhibitors
- GSE185651 Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1 mediated cell-intrinsic resistance 28 samples shares inhibition, resistance, inhibitors
- GSE304126 CDK8 inhibition sequesters Med1 at EWS-FLI enhancers [RNA-Seq] 68 samples shares cdk8, inhibition
- GSE295260 CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation 40 samples shares cdk4, inhibition
- GSE323965 Transcriptional signatures indicating RB function may predict response to CDK4/6 inhibition in endometrial cancer [RNA-Seq] 39 samples shares cdk4, inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.